Cure My Disease

Don't miss your cure!

 Log in / Sign up

Does the form of a supplement change how well the body absorbs it?

NCT ID NCT07804758

Knowledge-focused Sponsor: S&R Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests whether a liposomal form of the supplement palmitoylethanolamide (PEA) is absorbed into the body better than an ultra-micronized form. Six healthy adults will take a single 600 mg dose of each version, with a week between doses, and give blood samples over 24 hours. Researchers will compare how much PEA reaches the bloodstream and how quickly it is cleared. The goal is to see if the delivery method affects the supplement's availability in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two oral forms of the dietary supplement palmitoylethanolamide (PEA): an ultra-micronized version and a liposomal version, each given as a single 600 mg dose.
What this could lead to
If one form is absorbed better, it could point to a more effective way to deliver PEA supplements.
What could go wrong
This is a very small early study in healthy people, so results may not apply to the general public or to people with health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Apr 2026

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-70 years * BMI 18-30 kg/m² * Healthy participants * Written informed consent Exclusion Criteria: * Use of PEA-based supplements in the preceding 2 weeks. * Significant liver, kidney, gastrointestinal or metabolic conditions. * Known allergy or intolerance to PEA or excipients. * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liposomal encapsulation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liposomal encapsulation Palmitoylethanolamide PK in healthy volunteers

Contacts and locations

Locations

  • Crabion S.R.L.

    Corciano, PG, 06073, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.